Cohen Adi, Sambrook Philip, Shane Elizabeth
Department of Medicine, Duke University, Durham, North Carolina, USA.
J Bone Miner Res. 2004 Dec;19(12):1919-32. doi: 10.1359/JBMR.040912. Epub 2004 Sep 20.
Organ transplant recipients experience rapid bone loss and high fracture rates, particularly during the early post-transplant period. Early rapid bone loss occurs in the setting of uncoupled bone turnover with increased bone resorption and decreased bone formation. Because there are no clinical factors that reliably predict post-transplant bone loss and fractures in the individual patient, all transplant recipients should be considered candidates for early preventive therapy for osteoporosis. Long-term transplant recipients with densitometric osteoporosis and/or fractures should also receive treatment. Although active metabolites of vitamin D and bisphosphonates have both shown efficacy, data from clinical trials suggest that bisphosphonates are the safest and most consistently effective agents for the prevention and treatment of post-transplantation osteoporosis in adults. Kidney transplant recipients represent a special population, and more research is needed to delineate the risks and benefits of treating bone disease in these patients.
器官移植受者会经历快速的骨质流失和高骨折率,尤其是在移植后的早期阶段。早期快速骨质流失发生在骨转换失衡的情况下,骨吸收增加而骨形成减少。由于没有临床因素能够可靠地预测个体患者移植后的骨质流失和骨折情况,所有移植受者都应被视为骨质疏松早期预防性治疗的候选对象。患有密度测定性骨质疏松症和/或骨折的长期移植受者也应接受治疗。尽管维生素D的活性代谢物和双膦酸盐都已显示出疗效,但临床试验数据表明,双膦酸盐是预防和治疗成人移植后骨质疏松症最安全、最有效的药物。肾移植受者是一个特殊群体,需要更多研究来阐明治疗这些患者骨病的风险和益处。